Core Viewpoint - Nanwei Technology experienced a decline of 5.92% on November 21, with a trading volume of 157 million yuan, indicating potential market volatility and investor sentiment concerns [1] Financing Summary - On November 21, Nanwei Technology had a financing buy-in amount of 19.78 million yuan and a financing repayment of 26.99 million yuan, resulting in a net financing outflow of 7.21 million yuan [1] - As of November 21, the total financing and securities lending balance for Nanwei Technology was 385 million yuan, with the current financing balance at 383 million yuan, accounting for 3.55% of the circulating market value, which is above the 90th percentile level over the past year [1] - The company repaid 1,900 shares in securities lending and sold 2,000 shares on the same day, with a selling amount of 53,400 yuan, while the securities lending balance was 1.49 million yuan, also exceeding the 90th percentile level over the past year [1] Company Overview - Nanwei Technology, established on October 22, 2007, and listed on June 23, 2021, specializes in the research, large-scale production, sales, and application services of high-performance nano-microsphere materials [2] - The company's main business revenue composition includes: chromatography fillers and chromatography media products (57.62%), chromatography analysis instruments and accessories (19.72%), liquid chromatography columns and sample pretreatment products (10.44%), protein chromatography systems and accessories (5.02%), microsphere products for optoelectronics (3.98%), and others [2] - As of September 30, the number of shareholders for Nanwei Technology was 16,100, an increase of 6.57% from the previous period, with an average of 25,091 circulating shares per person, a decrease of 6.16% [2] Financial Performance - For the period from January to September 2025, Nanwei Technology achieved an operating income of 671 million yuan, representing a year-on-year growth of 22.01%, and a net profit attributable to the parent company of 108 million yuan, reflecting a significant year-on-year increase of 156.56% [2] Dividend Information - Since its A-share listing, Nanwei Technology has distributed a total of 115 million yuan in dividends, with 86.84 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders of Nanwei Technology, the China Europe Medical Health Mixed A Fund (003095) ranked as the tenth largest shareholder, holding 6.93 million shares, a decrease of 1.26 million shares from the previous period [3]

Group 1 - The core business of Nanwei Technology involves the research, large-scale production, sales, and application services of high-performance nano microsphere materials, serving clients in biomedicine, flat panel displays, analytical testing, and in vitro diagnostics [2] - As of September 30, 2025, Nanwei Technology achieved operating revenue of 671 million yuan, representing a year-on-year growth of 22.01%, and a net profit attributable to shareholders of 108 million yuan, with a significant year-on-year increase of 156.56% [2] - The company has distributed a total of 115 million yuan in dividends since its A-share listing, with 86.84 million yuan distributed over the past three years [3] Group 2 - On November 14, Nanwei Technology's stock price fell by 1.02%, with a trading volume of 142 million yuan [1] - The financing buy-in amount for Nanwei Technology on November 14 was 22.54 million yuan, while the financing repayment was 21.62 million yuan, resulting in a net financing buy-in of 918,600 yuan [1] - The total balance of margin trading for Nanwei Technology as of November 14 was 363 million yuan, with the financing balance accounting for 2.98% of the circulating market value, indicating a high level compared to the past year [1]

Core Viewpoint - Nanwei Technology experienced a decline of 2.94% in stock price on October 9, with a trading volume of 199 million yuan, indicating a potential shift in investor sentiment [1] Financing Summary - On October 9, Nanwei Technology had a financing buy-in amount of 23.78 million yuan and a financing repayment of 29.94 million yuan, resulting in a net financing outflow of 6.16 million yuan [1] - The total financing and securities balance for Nanwei Technology reached 351 million yuan, with the financing balance accounting for 3.09% of the circulating market value, indicating a high level compared to the past year [1] - The company had a financing buy-in of 23.78 million yuan on the same day, with a financing balance of 350 million yuan, which is above the 80th percentile of the past year [1] Securities Lending Summary - On October 9, Nanwei Technology repaid 4,287 shares in securities lending and sold 3,700 shares, with a selling amount of 103,700 yuan based on the closing price [1] - The remaining securities lending volume was 37,400 shares, with a balance of 1.05 million yuan, also exceeding the 80th percentile of the past year [1] Company Overview - Nanwei Technology, established on October 22, 2007, and listed on June 23, 2021, specializes in the research, production, and sales of high-performance nano-microsphere materials for various applications, including biomedicine and diagnostics [2] - The company's revenue composition includes 57.62% from chromatography fillers and media, 19.72% from chromatography instruments and accessories, and 10.44% from liquid chromatography columns and sample pretreatment products [2] - As of June 30, 2025, Nanwei Technology reported a revenue of 414 million yuan, a year-on-year increase of 21.74%, and a net profit attributable to shareholders of 63.31 million yuan, reflecting a growth of 40.52% [2] Dividend Summary - Since its A-share listing, Nanwei Technology has distributed a total of 115 million yuan in dividends, with 86.84 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders for Nanwei Technology was 15,100, an increase of 2.29% from the previous period, with an average of 26,739 circulating shares per person, a decrease of 2.24% [2][3]